<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878136</url>
  </required_header>
  <id_info>
    <org_study_id>13011803</org_study_id>
    <nct_id>NCT01878136</nct_id>
  </id_info>
  <brief_title>Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <official_title>Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the hypothesis that the administration of intraventricular tPA
      reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent
      hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Composite Primary Outcome</measure>
    <time_frame>1-60 days after SAH</time_frame>
    <safety_issue>No</safety_issue>
    <description>The composite primary outcome will consist of the rates of ventriculoperitoneal shunt (VPS) placement, clinically significant vasospasm, and death.  VPS placement serves as surrogate measure of hydrocephalus.  These outcomes will be measured during the patient's hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of new intracranial hemorrhage</measure>
    <time_frame>1-14 days after SAH</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>New intracranial hemorrhage will be defined as any new parenchymal or ventricular hemorrhage occurring after the first dose of study drug/placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial infection</measure>
    <time_frame>1-14 after SAH</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The presence of infection will require identification of an offending organism via CSF cultures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Vasospasm</condition>
  <condition>Cerebral Aneurysm</condition>
  <condition>Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>Intraventricular tPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tissue Plasminogen Activator (tPA)
Dose:  1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration:  Intraventricular; via previously placed external ventricular drain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo
Dose 1 mL sterile saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <description>Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)</description>
    <arm_group_label>Intraventricular tPA</arm_group_label>
    <other_name>Activase</other_name>
    <other_name>Alteplase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years old.

          -  SAH due to aneurysm, as determined by CT angiogram or cerebral angiogram.

          -  Modified Fisher (mF) grade 3 or 4 SAH, defined as thick cisternal blood without
             (grade 3) or with (grade 4) intraventrciular blood.

          -  Exclusion of the aneurysm from the parent circulation by endovascular embolization
             (Raymond class I or II) within 48 hours of ictus.

          -  Ventriculostomy placement must occur prior to randomization.

          -  Informed consent obtained from the patient or patient's decision maker

        Exclusion Criteria:

          -  Determination by treating physician(s) that no ventriculostomy is needed.

          -  Presence of intrinsic clotting disorders (e.g. due to hepatic failure, nephrotic
             syndrome, etc).  Subjects whose pharmacologic anticoagulation is reversed, as
             determined by PT/INR, PTT within our institution's normal range, will be permitted to
             participate in this study.

          -  Presence of significant anemia, defined as hemoglobin &lt; 8 gm/dL.

          -  Patients who undergo endovascular techniques requiring post-operative dual
             anti-platelet therapy.

          -  Residual aneurysm sac filling (Raymond class III occlusion).

          -  Aneurysm or vessel perforation during the endovascular procedure.

          -  Presence of craniectomy.

          -  Significant neurologic disability prior to the onset of SAH.

          -  Determination that administration of tPA/placebo cannot be initiated within 72 hours
             of symptom onset.

          -  Presence of untreated intracranial aneurysms larger than 3mm on CT angiography or
             cerebral angiogram.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Munich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roham Moftakhar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rush University Medical Center, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Munich, MD</last_name>
    <phone>3129421854</phone>
    <email>Stephan_Munich@Rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol MacPherson</last_name>
    <phone>3129428614</phone>
    <email>Carol_MacPherson@Rush.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Munich, MD</last_name>
      <phone>312-942-1854</phone>
      <email>Stephan_Munich@Rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roham Moftakhar, MD</last_name>
      <phone>3129421854</phone>
      <email>Roham_Moftakhar@Rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Munich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Johnson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Panos, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roham Moftakhar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Stephan Munich</investigator_full_name>
    <investigator_title>Neurosurgery Resident</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
